Keros Therapeutics, Inc.
KROS
$9.93
-$0.14-1.39%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 367.00K | 385.00K | 14.26M | 18.17M | 211.25M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 367.00K | 385.00K | 14.26M | 18.17M | 211.25M |
| Cost of Revenue | 16.10M | 17.81M | 19.52M | 43.50M | 48.71M |
| Gross Profit | -15.73M | -17.43M | -5.26M | -25.34M | 162.54M |
| SG&A Expenses | 10.15M | 11.74M | 10.13M | 14.48M | 10.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.24M | 29.56M | 29.65M | 57.99M | 59.21M |
| Operating Income | -25.88M | -29.17M | -15.38M | -39.82M | 152.04M |
| Income Before Tax | -23.71M | -24.98M | -8.70M | -32.92M | 158.49M |
| Income Tax Expenses | -- | -1.51M | -1.42M | -2.22M | 10.04M |
| Earnings from Continuing Operations | -23.71M | -23.46M | -7.28M | -30.70M | 148.45M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -23.71M | -23.46M | -7.28M | -30.70M | 148.45M |
| EBIT | -25.88M | -29.17M | -15.38M | -39.82M | 152.04M |
| EBITDA | -25.47M | -28.77M | -14.99M | -39.45M | 152.38M |
| EPS Basic | -1.21 | -0.86 | -0.18 | -0.76 | 3.66 |
| Normalized Basic EPS | -0.75 | -0.57 | -0.13 | -0.51 | 2.44 |
| EPS Diluted | -1.21 | -0.86 | -0.18 | -0.76 | 3.62 |
| Normalized Diluted EPS | -0.75 | -0.57 | -0.13 | -0.51 | 2.41 |
| Average Basic Shares Outstanding | 19.63M | 27.20M | 40.62M | 40.61M | 40.56M |
| Average Diluted Shares Outstanding | 19.63M | 27.20M | 40.62M | 40.61M | 41.02M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |